Synmosa Biopharma Market Cap ($432.69 Million)
Market Cap & Net Worth: Synmosa Biopharma (4114)
Synmosa Biopharma market cap. Synmosa Biopharma (TWO:4114) has a market capitalization of $432.69 Million (NT$13.73 Billion) as of November 8, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #12641 globally and #455 in its home market, demonstrating a -6.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Synmosa Biopharma's stock price NT$27.20 by its total outstanding shares 504921636 (504.92 Million). Also see 4114 cash generation efficiency for how efficiently the company converts equity into cash flow.
Synmosa Biopharma Market Cap History (2015–2026)
Synmosa Biopharma market cap history from 2015 to 2026. Data shows growth from $215.70 Million to $432.69 Million (7.55% CAGR). Check Synmosa Biopharma (4114) stock price for real-time trading data and today's change.
Synmosa Biopharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Synmosa Biopharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 4114 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.08x
Synmosa Biopharma's market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.63x
Synmosa Biopharma's market cap is 0.63 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $198.75 Million | $1.87 Billion | $166.65 Million | 0.11x | 1.19x |
| 2017 | $192.61 Million | $1.86 Billion | $4.69 Million | 0.10x | 41.09x |
| 2018 | $226.17 Million | $2.36 Billion | $430.90 Million | 0.10x | 0.52x |
| 2019 | $224.17 Million | $2.68 Billion | $47.09 Million | 0.08x | 4.76x |
| 2020 | $254.41 Million | $3.04 Billion | $638.11 Million | 0.08x | 0.40x |
| 2021 | $267.47 Million | $3.23 Billion | $303.86 Million | 0.08x | 0.88x |
| 2022 | $618.65 Million | $4.39 Billion | $799.09 Million | 0.14x | 0.77x |
| 2023 | $549.00 Million | $5.14 Billion | $594.83 Million | 0.11x | 0.92x |
| 2024 | $548.82 Million | $5.55 Billion | $684.68 Million | 0.10x | 0.80x |
| 2025 | $515.41 Million | $6.19 Billion | $821.85 Million | 0.08x | 0.63x |
Competitor Companies of 4114 by Market Capitalization
Companies near Synmosa Biopharma in the global market cap rankings as of November 8, 2026. Also see total assets of Synmosa Biopharma for a full breakdown of the balance sheet.
Key companies related to Synmosa Biopharma by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Synmosa Biopharma (2015–2026)
Market capitalization of Synmosa Biopharma from 2015 to today. Between 2015 and today, Synmosa Biopharma's market cap moved from $215.70 Million to $ 432.69 Million, with a yearly change of 7.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$432.69 Million | -16.05% |
| 2025 | NT$515.41 Million | -6.09% |
| 2024 | NT$548.82 Million | -0.03% |
| 2023 | NT$549.00 Million | -11.26% |
| 2022 | NT$618.65 Million | +131.29% |
| 2021 | NT$267.47 Million | +5.13% |
| 2020 | NT$254.41 Million | +13.49% |
| 2019 | NT$224.17 Million | -0.89% |
| 2018 | NT$226.17 Million | +17.43% |
| 2017 | NT$192.61 Million | -3.09% |
| 2016 | NT$198.75 Million | -7.86% |
| 2015 | NT$215.70 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Synmosa Biopharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $432.69 Million USD |
| MoneyControl | $432.69 Million USD |
| MarketWatch | $432.69 Million USD |
| marketcap.company | $432.69 Million USD |
| Reuters | $432.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, gr… Read more